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Abstract
Objectives: We compared the transperineal MRI/ultrasound-
fusion biopsy (fusPbx) to transrectal systematic biopsy (sys-
Pbx) in patients with previously negative biopsy and investi-
gated the prediction of tumour aggressiveness with regard 
to radical prostatectomy (RP) specimen. Material and Meth-
ods: A total of 710 patients underwent multiparametric 
magnetic resonance imaging (mpMRI), which was evaluated 
in accordance with Prostate Imaging Reporting and Data 
System (PI-RADS). The maximum PI-RADS (maxPI-RADS) was 
defined as the highest PI-RADS of all lesions detected in 
mpMRI. In case of proven prostate cancer (PCa) and per-
formed RP, tumour grading of the biopsy specimen was 
compared to that of the RP. Significant PCa (csPCa) was de-
fined according to Epstein criteria. Results: Overall, scPCa 
was detected in 40% of patients. The detection rate of scPCa 
was 33% for fusPbx and 25% for sysPbx alone (p < 0.005). 
Patients with a maxPI-RADS ≥3 and a prostate specific anti-
gen (PSA)-density ≥0.2 ng/mL2 harboured more csPCa than 
those with a PSA-density < 0.2 ng/mL2 (41% [33/81] vs. 20% 
[48/248]; p < 0.001). Compared to the RP specimen (n = 140), 
the concordance of tumour grading was 48% (γ = 0.57), 36% 
(γ = 0.31) and 54% (γ = 0.6) in fusPbx, sysPbx and comPbx, 
respectively. Conclusions: The combination of fusPbx and 
sysPbx outperforms both biopsy modalities in patients with 
re-biopsy. Additionally, the PSA-density may represent a 
predictor for csPCa in patients with maxPI-RADS ≥3.
© 2018 S. Karger AG, Basel
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Introduction
In the last decade, multiparametric magnetic reso-
nance imaging (mpMRI) of the prostate has become an 
established diagnostic tool for prostate cancer (PCa) [1, 2]. 
Targeted biopsy of tumour-suspicious lesions in mpMRI 
has been demonstrated as a promising method for PCa 
detection [3–6]. Moreover, it has been shown that target-
ed biopsy detects significantly more high-risk PCa than 
systematic biopsy (sysPbx) alone [3–6]. As a consequence, 
most of the current guidelines recommend mpMRI and 
consecutive targeted biopsy in patients in whom suspicion 
of PCa remained after a negative biopsy [7–10]. Previous 
studies have reported the benefit of MRI/ultrasound-fu-
sion biopsy (fusPbx) in higher detection rates for clini-
cally significant PCa (csPCa) in both biopsy-naïve pa-
tients and patients with previously negative prostate bi-
opsy [4–6, 11–15]. 
In addition, fusPbx has shown a higher concordance 
of tumour grading compared to that of the radical pros-
tatectomy (RP) specimen [16–19]. Therefore, fusPbx rep-
resents a more accurate tool in terms of prediction of tu-
mour aggressiveness.
The aim of this study was to assess the value of 
mpMRI by comparing targeted fusPbx with sysPbx and 
the combination of both biopsy modalities (comPbx) in 
patients with previously negative biopsy. Additionally, 
in patients with proven PCa undergoing RP, we com-
pared the tumour grading of the biopsy to that of the 
RP specimen.
Patients and Methods
Recruitment and Study Endpoints
Patients with suspected PCa due to elevated prostate specific 
antigen (PSA) level (≥4.0 ng/mL) and/or abnormal digital-rectal 
examination and at least one previously negative prostate biopsy 
were included. Patients with mpMRI, without evaluation of lesions 
according to START criteria [20–22], were excluded.
This study was approved by the Institutional Review Board of 
the Technische Universität Dresden (Votes: EK53022014).
Patients underwent transperineal fusPbx combined with tran-
srectal sysPbx. The primary endpoint was the proportion of pa-
tients diagnosed with csPCa, defined according to Epstein criteria 
(presence of Gleason Score [GS] ≥7 [3 + 4] or a GS 6 [3 + 3] with 
a cancer core involvement ≥50% or ≥3 positive cores) in at least 
one of both biopsy modalities. 
Investigations of Multiparametric MRI
Prostate mpMRIs were performed on 3-Tesla MR-systems 
by  Siemens (Siemens Medical Solutions, Erlangen, Germany) 
without the use of endorectal-coils. MpMRI protocols included 
T2-weighted images in axial and coronal orientations, T1-weight-
ed images, diffusion-weighted images, dynamic contrast-en-
hanced imaging, and contrast-enhanced T1-weighted images in 
transverse orientation. The total mpMRI acquisition time was ap-
proximately 30 min. The evaluation of mpMRI-data was per-
formed by 2 uro-radiologists with an experience of 10 and 8 years 
in evaluating prostate mpMRI. 
Tumour-suspicious lesions were evaluated by the Prostate 
 Imaging Reporting and Data System (PI-RADS) classifications v1 
and  v2 [20–22]. The maximum PI-RADS (maxPI-RADS) in 
 mpMRI was defined as the lesion with the highest PI-RADS of all 
lesions per patient. Analysis of detection rates in lesions detected 
in mpMRI was performed on both patient-based (maxPI-RADS) 
and lesion-based (all lesions in mpMRI of all patients) levels. 
Prostate Biopsy and Histopathological Examination
The BioJet-System (d&k Technologies, Barum, Germany) was 
used for fusPbx, as described previously [23]. Briefly, fusPbx was 
performed in a transperineal approach while taking at least 2 cores 
per lesion depending on the size of the lesion. Due to a better tar-
geting of lesions located in the anterior zone of the prostate, the 
transperineal approach was chosen for targeted biopsy. Lesions 
classified as PI-RADS ≥2 were biopsied in a targeted fashion. Sub-
sequently, every patient underwent a conventional, transrectal 
 12-core sysPbx. The procedure was performed under general an-
aesthesia (larynx mask) or under sedation. Both biopsy modalities 
were performed by the same urologist. The detection rate of PCa 
in fusPbx and sysPbx were compared. The concordance, up- and 
downgrading of GS in PCa detected in fusPbx and sysPbx com-
pared to the GS of RP specimen were analysed. Tumour aggres-
siveness was expressed by GS. The pathological stage was deter-
mined according to the 2010 TNM classification. 
Statistical Analysis
Data were analysed using SPSS version 24.0 (IBM Corp., 
 Armonk, NY, USA). Categorical data are presented as absolute and 
relative frequencies. Continuous variables are described as means, 
complemented by median and range. The Student t test and the χ2 
test were applied to determine differences between continuous and 
categorical variables. The McNemar test was used to compare the 
detection rate of fusPbx with sysPbx and comPbx. A p value < 0.05 
was considered as statistically significant. Uni- and multivariate 
logistic regression analyses were used to evaluate the prediction of 
csPCa in prostate biopsy stratified to age, number of previous bi-
opsies, PSA, PSA-density, prostate volume, number of lesions, lo-
calisation of lesions, maxPI-RADS ≥3 and maxPI-RADS ≥4. The 
Goodman-Kruskal-gamma (γ) statistic was used as a measure of 
correlation between the tumour grading of the biopsy and RP spec-
imen. A γ = 1 indicates a concordance of 100%.
Results
Patients’ Characteristics and Detection Rates of csPCa 
in fusPbx and sysPbx
A total of 1,115 patients underwent comPbx at our in-
stitution from January 2013 to April 2017. Of which, 767 
patients with previously negative prostate biopsy and fur-
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ther suspicion of PCa underwent repeat biopsy. Fifty-sev-
en patients were excluded due to incomplete mpMRI 
data. Therefore, 710 patients were included in this study. 
Patients’ characteristics are depicted in Table 1. In comP-
bx, the overall PCa detection rate was 48% (338/710), 
whereby csPCa was detected in 40% (282/710). FusPbx 
detected more PCa of any GS than sysPbx (39% 
[275/710] vs. 32% [225/710]; p < 0.005). Moreover, fus-
Pbx detected more csPCa than sysPbx (33% [234/710] vs. 
25% [176/710]; p < 0.005). ComPbx outperforms fusPbx 
and sysPbx in the detection of csPCa (40 vs. 33% [p < 
0.005] and vs. 25% [p < 0.005], respectively). Regarding 
the missing rates of csPCa, fusPbx alone would have 
missed 17% (48/282) whereas sysPbx alone would have 
missed 38% (106/282).
Evaluation of mpMRI 
Regarding all mpMRI lesions detected in all included 
patients, 1,282 lesions were detected. CsPCa was found 
in 5% (13/239), 15% (78/523), 29% (107/369) and 62% 
(93/151) of lesions classified as PI-RADS 2, 3, 4 and 5, re-
spectively.
Regarding the maxPI-RADS, detection rate for csP-
Ca was 14% (11/81), 28% (70/248), 43% (110/257) and 
74% (91/124) in patients presenting maxPI-RADS2, 
maxPI-RADS3, maxPI-RADS4 and maxPI-RADS5, re-
spectively. 
In patients with maxPI-RADS2 (n = 81), csPCa was 
detected in 12% (n = 11) by sysPbx and in 7% (n = 6) by 
fusPbx (p = 0.219), respectively. Only in 1 patient with 
maxPI-RADS2, csPCa was detected by fusPbx alone. Pa-
tients presenting a maxPI-RADS ≥4 showed a higher de-
tection rate of csPCa than patients presenting a maxPI-
RADS ≤3 (53 [201/381] vs. 25% [81/329]; p < 0.001). Re-
garding the localisation of lesions harbouring csPCa (n = 
291), 41% (n = 121), 29% (n = 84) and 30% (n = 86) were 
located in the peripheral, central and anterior zone of the 
prostate, respectively.
Prediction of csPCa
In multivariate analysis, the strongest independent 
predictors for csPCa in comPbx and fusPbx were a high 
PSA value and density, a higher age, a small prostate, the 
evidence of at least one PI-RADS ≥4 lesion and an an-
teriorly located lesion. The localisation and grade of 
suspicion of the lesion did not predict csPCa in sysPbx 
(Table 2). 
Patients with maxPI-RADS ≤3 (n = 329) and a PSA 
density ≥0.2 ng/mL2 harboured more csPCa than those 
with a PSA density < 0.2 ng/mL2 (41% [33/81] vs. 20% 
[48/248]; p < 0.001). Table 3 represents detection rates 
of csPCa stratified to the PSA density and maxPI-
RADS.
Comparison of Biopsy Specimen with Prostatectomy 
Specimen
Around 41% (140/338) of patients with proven PCa un-
derwent RP whereby 26% (37/140) presented an unfavour-
able pathological tumour stage (≥pT3). Five patients (4%) 
presented lymph node metastasis (pN1). In these patients, 
Table 1. Patients’ demographics, findings on mpMRI and histopa-
thology of prostate biopsy cores
Parameter Value
Age, years, median (IQR) 67 (61–72)
Number of previous prostate biopsies, median (IQR) 1 (1–2)
Number of patients with previous negative fusPbx 
combined with sysPbx, n (%) 38 (5)
PSA, ng/mL, median (IQR) 8.8 (6.3–12.9)
PSA density, ng/mL2, median (IQR) 0.15 (0.08–0.28)
Suspicious findings in DRE, n (%) 83 (12)
Prostate volume, mL, median (IQR) 50.0 (35.0–69.5)
Overall biopsy cores per patient, n, median (IQR) 19 (17–21)
Targeted biopsy cores per patient, n, median (IQR) 7 (5–9)
Systematic biopsy cores per patient, n, median (IQR) 12 (12–12)
Ratio of positive cores to total cores in targeted 
biopsy per patient, %, mean ± SEM 7±0.5
Ratio of positive cores to total cores in systematic 
biopsy per patient, %, mean ± SEM 18±1
Number of lesions/patient, n, median (IQR) 2 (1–2)
MRI before prostate biopsy, n
Total number of lesions
PI-RADS of lesion, n
2
3
4
5
1,282
239
523
369
151
maxPI-RADS, n (%)
2
3
4
5
81 (11)
248 (35)
257 (36)
124 (18)
Histological findings (n) in combined prostate biopsy
Gleason score of biopsy (combination 
of targeted and systematic biopsy), n
No tumour
3 + 3 = 6 (clinically significant 3 + 3 = 6#)
3 + 4 = 7
4 + 3 = 7
≥8
372
76 (20)
161
42
59
# Gleason score 3 + 3 = 6 and ≥50% tumour involvement or ≥ 3 cores 
positive.
IQR, interquartile range; SEM, standard error of the mean; PSA, pros-
tate specific antigen.
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the mpMRI did not show evidence of lymph node metas-
tasis; 6% (n = 9), 60% (n = 83), 26% (n = 36) and 8% (n = 
11) of patients demonstrated a GS 6, GS 7 (3 + 4), GS 7 (4 
+ 3) and GS ≥8 PCa, respectively. In 1 patient, the GS could 
not be defined due to neoadjuvant androgen deprivation 
therapy. Clinically, no patient presented distant metastasis 
at the time of diagnosis. Concordance on GS between bi-
opsy and RP specimen was 48% (n = 67), 36% (n = 50) and 
54% (n = 75) in fusPbx, sysPbx and comPbx, respectively. 
Upgrading on GS between biopsy and RP specimen oc-
curred in 36% (n = 50), 51% (n = 72) and 25% (n = 35) in 
fusPbx, sysPbx and comPbx, respectively. Gamma correla-
tion for the detection of any PCa was γ = 0.60 for comPbx, 
γ = 0.57 for fusPbx alone and γ = 0.31 for sysPbx alone. 
Discussion
We demonstrated that fusPbx detected significantly 
more PCa of any GS and especially csPCa than sysPbx in 
patients with previously negative prostate biopsy and 
further suspicion of PCa. More important, fusPbx seems 
to be a better predictor than sysPbx for the final tumour 
grading in the RP specimen. Especially, the latter is es-
sential for counselling patients for further treatment op-
tions. Moreover, a PSA density ≥0.2 ng/mL2 seems to be 
predictive for csPCa in patients presenting lesions classi-
fied as maxPI-RADS ≤3, suggesting that PSA density 
may represent a predictor for csPCa in this subgroup of 
patients.
Table 3. Detection rates and accuracy for clinically significant PCa in patients with PSA density ≥0.2 vs. <0.2 ng/mL2 stratified to the 
maxPI-RADS
PSA-density, 
ng/mL2
ComPbx FusPbx SysPbx
<0.2 ≥0.2 p value accuracy <0.2 ≥0.2 p value accuracy <0.2 ≥0.2 p value accuracy
MaxPI-RADS 2 
(n = 81), % (n)
11 (7/61) 20 (4/20) 0.334 0.72 7 (4/61) 10 (2/20) 0.610 0.73 10 (6/61) 20 (4/20) 0.230 0.73
MaxPI-RADS 3 
(n = 248), % (n)
22 (41/187) 48 (29/61) <0.005 0.71 16 (30/187) 31 (19/61) 0.010 0.71 14 (27/187) 36 (22/61) <0.005 0.73
MaxPI-RADS 4
(n = 257), % (n)
29 (45/155) 64 (65/102) <0.005 0.68 23 (36/155) 57 (58/102) <0.005 0.69 20 (30/155) 32 (33/102) 0.018 0.61
MaxPI-RADS 5
(n = 124), % (n)
53 (25/47) 86 (66/77) <0.005 0.71 47 (22/47) 83 (64/77) <0.005 0.71 32 (15/47) 51 (39/77) 0.41 0.57
PSA, prostate specific antigen.
Table 2. Multivariate logistic regressions analysis for the determination of predictors for the detection of significant prostate cancer 
in the combination of fusion biopsy and systematic biopsy (comPbx), fusion biopsy alone (fusPbx) and systematic biopsy alone 
(sysPbx)
Co-variate Comparison ComPbx FusPbx SysPbx
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Age, years, median 67a ≥ vs. < median 2.0 (1.4–2.9) <0.005 1.6 (1.1–2.3) 0.017 1.8 (1.2–2.5) 0.002
Number of previous biopsies > vs. ≤1 biopsy – – – – 0.5 (0.37–0.8) 0.002
PSA, median 8.8 ng/mL ≥ vs. < median 2.4 (1.6–3.5) <0.005 2.4 (1.6–3.7) <0.005 1.8 (1.2–2.8) 0.009
PSA density ≥ vs. <0.2 ng/mL2 1.8 (1.2–2.8) 0.005 1.6 (1.03–2.5) 0.036 1.6 (0.9–2.4) 0.454
Prostate volume, median 50 mL ≥ vs. < median 0.3 (0.2–0.5) <0.005 0.3 (0.2–0.5) <0.005 0.5 (0.3–0.7) <0.005
Number of lesions > vs. ≤1 lesion 0.62 (0.4–0.9) 0.011 0.7 (0.5–1.01) 0.057 0.5 (0.4–0.7) 0.002
Localisation of lesions Anterior zone vs. 
peripheral and central
1.9 (1.2–2.8) 0.004 2.5 (1.6–3.7) <0.005 – –
MaxPI-RADS ≥3 ≥3 vs. ≤2 2.4 (1.2–5.1) 0.018 2.9 (1.2–7.3) 0.023 1.6 (0.8–3.6) 0.188
MaxPI-RADS ≥4 ≥4 vs. ≤3 1.9 (1.3–2.9) 0.001 2.5 (1.6–3.8) <0.005 2.3 (0.8–1.9) 0.255
If the co-variate was not statistically significant in univariate analysis, it was not considered for multivariate analysis. Significant parameters are de-
picted in bold. PSA, prostate specific antigen.
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Previous studies reported that the suspicion level of le-
sions described in mpMRI was positively associated with 
the detection rate of csPCa [3, 4, 24]. An enhancement of 
diagnostic accuracy of mpMRI for the detection of high-
risk PCa was demonstrated in biopsy-naïve patients [11]. 
Moreover, the superiority of fusPbx versus sysPbx was 
shown in a recently published prospective trial evaluating 
mpMRI and targeted biopsy alone in case of suspicious 
lesions versus sysPbx alone without the integration of 
mpMRI [12]. As expected, patients presenting PI-RADS 
≥4 lesions showed a higher detection rate of csPCa than 
patients presenting PI-RADS ≤3 lesions in our cohort. 
Additionally, multivariate analysis demonstrated that the 
presence of maxPI-RADS ≥4 was an independent predic-
tor for csPCa in comPbx and fusPbx, but not for sysPbx. 
Regarding missing rates of csPCa, our study revealed 
that fusPbx alone would have missed 17% whereas sysPbx 
alone would have missed 38%. Other studies showed that 
sysPbx alone would still detect an important number of 
intermediate and high-risk PCa either in the case of a neg-
ative mpMRI or one that was missed in targeted biopsy 
[25, 26]. Filson et al. [27] also reported that csPCa would 
be missed in up to 12% if systematic biopsies were not 
performed in patients without tumour-suspicious lesions 
in mpMRI, demonstrating that fusPbx cannot still replace 
sysPbx. As shown in recent studies [21, 28, 29], it is still 
important to consider clinical factors in the decision for 
further biopsies in patients with previously negative bi-
opsy beside the mpMRI. In the current study, multivari-
ate analysis showed that beside the evidence of a highly 
suspicious and anteriorly located lesion in mpMRI, clini-
cal factors like a higher age, higher PSA levels and PSA 
density are associated with the detection of csPCa.
Moreover, Hansen et al. [3] suggested that the evi-
dence of a negative or low-suspicious mpMRI (PI-RADS 
≤3) associated with a PSA density ≤0.2 ng/mL2 may omit 
an immediate repeat prostate biopsy in patients with a 
previously negative prostate biopsy. Moreover, Gomez 
Rivas et al. [30] suggested in a systematic review about the 
value of intermediate or equivocal lesions that the com-
bination of mpMRI, clinical parameters, biomarkers and 
nomograms may allow a more accurate decision for or 
against a biopsy in these patients. Also in our cohort, es-
pecially patients with maxPI-RADS ≤3 and a PSA density 
≥0.2 ng/mL2 showed a higher detection rate of csPCa 
highlighting the importance of PSA density in the predic-
tion of csPCa in this subgroup. However, the detection 
rate of csPCa in patients with maxPI-RADS ≤3 and PSA 
density < 0.2 ng/mL2 is still 20%. Consequently, we still 
recommend prostate biopsy in these patients. In this 
study, most of the lesions harbouring csPCa are located 
anteriorly or in the transition zone of the prostate and are 
not easily reached by sysPbx. Also, other study groups 
reported that anteriorly located tumours are frequently 
identified using MRI targeted biopsy [31].
Additionally, we showed that 57% of patients with max-
PI-RADS of 4 and 26% of patients with maxPI-RADS of 5 
did not harbour csPCa. Chelluri et al. demonstrated that 
most patients with mainly low- or intermediate-suspicious 
lesions on initial mpMRI and negative targeted biopsies 
presented in a follow-up targeted biopsy no PCa or low-
grade PCa [32]. In contrast, Costa et al. [33] found that in 
patients with high-suspicious lesions in mpMRI and nega-
tive targeted biopsy, a high proportion of men harboured 
intermediate- or high-risk PCa in these lesions either in re-
peat targeted biopsy or in comparison to the RP specimen. 
Our present findings demonstrated that comPbx is the 
most accurate predictor for final tumour grading in the 
RP specimen. Especially, fusPbx seems to majorly con-
tribute to the prediction of tumour aggressiveness in 
comPbx in a repeat biopsy setting. Previous studies also 
demonstrated that fusPbx showed a better concordance 
of tumour grading in RP specimen than sysPbx. Howev-
er, comPbx outperforms fusPbx and sysPbx alone [5, 16–
19]. Based on these data, comPbx should be offered to 
patients with previous negative sysPbx. In case of a re-
peated negative comPbx and the presence of high-suspi-
cious lesions in mpMRI or further PSA progress, a follow-
up biopsy should be performed in a short interval. Pa-
tients with low-suspicious lesions and low PSA density 
should still undergo sysPbx.
Our study has several limitations. First, fusPbx and 
sysPbx were performed consecutively by the same urolo-
gist in an unblinded manner. Consequently, knowledge 
about the location of lesions in mpMRI could have 
 influenced the operator in needle placement during sys-
Pbx and could have resulted in a falsely high detection 
rate in sysPbx. Currently, data of the recently published 
PRECISION trial showed a superiority of fusPbx in biop-
sy-naïve patients [12]. Furthermore, prospective data are 
needed to clarify this issue in a re-biopsy cohort as 
well. Second, we did not perform a direct comparison of 
mpMRI and whole-mount prostatectomy specimen as 
previously described [17]. Data of this study are based 
only on the reported GS of biopsy and RP specimen; how-
ever, we performed the comparison in only 41% of pa-
tients with proven PCa. Lastly, we did not perform a stan-
dardised long-term follow-up assessment, especially in 
patients with negative repeat biopsy and higher suspi-
cious levels in mpMRI. Recently published data have sug-
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gested that negative targeted biopsies do not exclude 
 csPCa in this subgroup of patients [33]. This should be 
considered in the further follow-up of these patients.
Conclusions
For men with previously negative biopsy, the combi-
nation of comPbx outperforms both biopsy modalities 
alone regarding the detection rate of csPCa and concor-
dance of tumour grading compared to the RP specimen. 
However, the missing rate of csPCa in fusPbx is still high. 
Additionally, the PSA density may represent a predictor 
for csPCa in comPbx in patients with maxPI-RADS ≤3. 
Therefore, comPbx should still be recommended in pa-
tients with previously negative prostate biopsy and per-
sisting suspicion of PCa.
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